Rifaximin
Tropical Enteropathy
Washington University School of MedicineSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Tropical Enteropathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ipv (Inactivated Polio Vaccine) International Vaccine Institute | Phase 3 | BB |
Rotarix University of Vermont | Phase 3 | BB |
Same molecule, other indications
Rifaximin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →